小细胞肺癌(SCLC)约占全部肺癌的20%～25%,但其特点是早期播散和快速生长。约2/3患者诊断时已属广泛期病变,未经治疗的广泛期患者仅能生存6～12周,而局限期患者也只有3～6个月。SCLC对化疗敏感,有效率达70%～90%,并且化疗能明显改善患者的生存,但多数患者仍然复发,且多在2年内 Small cell lung cancer (SCLC) accounts for about 20% to 25% of all lung cancers, but is characterized by early dissemination and rapid growth. Approximately two-thirds of patients have been diagnosed with extensive disease at the time of diagnosis, with untreated extensive patients surviving only for 6 to 12 weeks and those with limited duration being only 3 to 6 months. SCLC is sensitive to chemotherapy, the effective rate of 70% to 90%, and chemotherapy can significantly improve patient survival, but most patients still relapse, and more than 2 years